Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Shares Issued (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Shares Issued data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Shares Issued fell 99.68% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $2.4 million, down 99.45%, while the annual FY2025 figure was $2.4 million, 99.45% down from the prior year.
  • Shares Issued reached $1.3 million in Q4 2025 per CLDX's latest filing, up from $774000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $432.3 million in Q1 2024 and bottomed at -$424.8 million in Q2 2024.
  • Average Shares Issued over 5 years is $46.2 million, with a median of $734000.0 recorded in 2023.
  • The widest YoY moves for Shares Issued: up 62191.07% in 2024, down 319478.95% in 2024.
  • A 5-year view of Shares Issued shows it stood at $267.8 million in 2021, then crashed by 99.48% to $1.4 million in 2022, then soared by 15322.08% to $215.1 million in 2023, then surged by 96.87% to $423.5 million in 2024, then tumbled by 99.68% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $1.3 million in Q4 2025, $774000.0 in Q3 2025, and $63000.0 in Q2 2025.